|
| 36166727 | Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. | J Clin Oncol | 2023 |
| 36356599 | Non-viral precision T cell receptor replacement for personalized cell therapy. | Nature | 2023 |
| 36166727 | Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. | J Clin Oncol | 2023 |
| 35998300 | Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. | J Clin Oncol | 2023 |
| 36416874 | CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma. | Cancer Discov | 2023 |
| 36416836 | Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial. | JAMA Oncol | 2023 |
| 37592104 | Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. | Nat Med | 2023 |
| 37803324 | ERK mediates interferon gamma-induced melanoma cell death. | Mol Cancer | 2023 |
| 37801341 | Antitumor Immune Responses in B2M-Deficient Cancers. | Cancer Immunol Res | 2023 |
| 37891435 | T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome. | Nat Rev Drug Discov | 2023 |
| 37871333 | Infusion Product TNFα, Th2, and STAT3 Activities Are Associated with Clinical Responses to Transgenic T-cell Receptor Cell Therapy. | Cancer Immunol Res | 2023 |
| 37699333 | Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression. | Cancer Cell | 2023 |
| 37621406 | A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer. | Cancer Res Commun | 2023 |
| 37348035 | Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma. | J Clin Oncol | 2023 |
| 37156551 | Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade. | J Immunother Cancer | 2023 |
| 36518078 | Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials. | Mol Ther | 2023 |
| 37027480 | Computational prediction of MHC anchor locations guides neoantigen identification and prioritization. | Sci Immunol | 2023 |
| 36890230 | Neoantigen-targeted CD8<sup>+</sup> T cell responses with PD-1 blockade therapy. | Nature | 2023 |
| 37196065 | Clonally expanded, thyrotoxic effector CD8<sup>+</sup> T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditis. | Sci Transl Med | 2023 |
| 36700848 | Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma. | Cancer Discov | 2023 |
| 37192158 | IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing. | Proc Natl Acad Sci U S A | 2023 |
| 36624340 | Multimodal single-cell and whole-genome sequencing of small, frozen clinical specimens. | Nat Genet | 2023 |
| 37174027 | Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and a Literature Review. | Cancers (Basel) | 2023 |
| 37037616 | Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma. | Cancer Cell | 2023 |
| 37290925 | Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop. | J Immunother Cancer | 2023 |
| 37803324 | ERK mediates interferon gamma-induced melanoma cell death. | Mol Cancer | 2023 |
| 37801341 | Antitumor Immune Responses in B2M-Deficient Cancers. | Cancer Immunol Res | 2023 |
| 37592104 | Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. | Nat Med | 2023 |
| 37621406 | A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer. | Cancer Res Commun | 2023 |
| 37699333 | Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression. | Cancer Cell | 2023 |
| 37891435 | T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome. | Nat Rev Drug Discov | 2023 |
| 37871333 | Infusion Product TNFα, Th2, and STAT3 Activities Are Associated with Clinical Responses to Transgenic T-cell Receptor Cell Therapy. | Cancer Immunol Res | 2023 |
| 37192158 | IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing. | Proc Natl Acad Sci U S A | 2023 |
| 37290925 | Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop. | J Immunother Cancer | 2023 |
| 37156551 | Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade. | J Immunother Cancer | 2023 |
| 37348035 | Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma. | J Clin Oncol | 2023 |
| 37174027 | Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and a Literature Review. | Cancers (Basel) | 2023 |
| 37037616 | Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma. | Cancer Cell | 2023 |
| 37196065 | Clonally expanded, thyrotoxic effector CD8<sup>+</sup> T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditis. | Sci Transl Med | 2023 |
| 37027480 | Computational prediction of MHC anchor locations guides neoantigen identification and prioritization. | Sci Immunol | 2023 |
| 36890230 | Neoantigen-targeted CD8<sup>+</sup> T cell responses with PD-1 blockade therapy. | Nature | 2023 |
| 36624340 | Multimodal single-cell and whole-genome sequencing of small, frozen clinical specimens. | Nat Genet | 2023 |
| 36518078 | Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials. | Mol Ther | 2023 |
| 36416874 | CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma. | Cancer Discov | 2023 |
| 36416836 | Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial. | JAMA Oncol | 2023 |
| 36700848 | Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma. | Cancer Discov | 2023 |
| 35998300 | Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. | J Clin Oncol | 2023 |
| 36356599 | Non-viral precision T cell receptor replacement for personalized cell therapy. | Nature | 2023 |
| 34801354 | KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation. | Eur J Cancer | 2022 |
| 35653193 | Purine nucleoside phosphorylase enables dual metabolic checkpoints that prevent T cell immunodeficiency and TLR7-associated autoimmunity. | J Clin Invest | 2022 |